Regulatory milestones

Acura Pharmaceuticals Inc. (NASDAQ:ACUR) lost $0.17 (14%) to $1.06 last week after saying FDA advised the company that data from the Phase II Study 301 are "insufficient to support an intranasal abuse deterrence claim" for Acura's Vycavert, an oral, immediate-release formulation of hydrocodone with acetaminophen that uses the company's Aversion abuse-deterrent technology.